BBIO Presents Achondroplasia Data
BridgeBio Pharma presents additional data from its Phase 3 pivotal study of oral infigratinib in children with achondroplasia
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.